Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.56 |
| ▸ | PRF1 | P14222 | 2/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ESRRG | P62508 | 4/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133750 | 0.82 | APP (0.54) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL70783 | 0.81 | APP (0.67) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL13221507 | 0.80 | PRF1 (0.57) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL7010956 | 0.79 | CYP2A6 (0.54) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL2019002 | 0.79 | PRF1 (0.56) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL5760473 | 0.79 | CYP2E1 (0.54) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL9199395 | 0.79 | CYP2E1 (0.54) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL7905308 | 0.78 | APP (0.68) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL10472980 | 0.78 | APP (0.73) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 | |
| SCHEMBL16398737 | 0.78 | CYP2E1 (0.42) | HSD17B1HSD17B2PRF1CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-110914242-A | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3615514-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018201167-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | HSD17B1 2006/4885HSD17B2 2347/4885PRF1 1453/4885 |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | HSD17B1 1243/4885HSD17B2 1355/4885PRF1 1/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | HSD17B1 2006/4885HSD17B2 2347/4885PRF1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.